1. Pharmaceutical Coding and Artificial Intelligence Pharmacy Tools in the Era of Pharmacy 4.0: A Review
Tilak Vaishnav, Nikhil Prajapat, Puja Pragi, Aditya Nath Yogi, Durga Shankar Dhaker, Raghvendra Singh Bhadauria, Ashutosh Choubisa
Abstract
The pharmaceutical and healthcare sectors generate extensive amounts of structured and unstructured information throughout drug discovery, development, clinical research, manufacturing, dispensing, regulatory activities and post-marketing surveillance. Standardized pharmaceutical coding and digital technologies have therefore become important components of modern pharmacy practice. Pharmaceutical coding provides a structured approach for representing medicines, medical conditions, adverse drug reactions, therapeutic indications and other healthcare information through standardized classification systems and controlled terminologies. Systems such as the Medical Dictionary for Regulatory Activities (MedDRA), WHO Adverse Reaction Terminology (WHO-ART), Anatomical Therapeutic Chemical (ATC) classification and International Nonproprietary Names (INN) support consistency, data exchange, pharmacovigilance and drug-utilization research. At the same time, artificial intelligence (AI) and machine-learning technologies are increasingly being explored across the medicinal-product lifecycle. Potential applications include drug discovery, ADMET prediction, clinical trials, pharmacovigilance, regulatory affairs, pharmaceutical manufacturing and quality control. Various computational resources, including SwissADME, pkCSM, ProTox, RDKit, AutoDock Vina and AlphaFold, can support pharmaceutical research and data analysis. The integration of pharmaceutical coding with AI may facilitate structured data processing, pattern recognition and decision support within the Pharmacy 4.0 framework. However, limitations involving data quality, algorithmic bias, transparency, privacy, validation, reliability, regulatory uncertainty and human oversight remain important considerations. This review discusses the role of pharmaceutical coding, AI-based pharmacy tools and their relationship with pharmacovigilance and pharmaceutical regulation, with particular relevance to the Indian pharmaceutical system.
2. India’s Pharmaceutical Self-Reliance: Regulatory Affairs, API Import Dependence, and Strategies for Strengthening Domestic Manufacturing
Siddharth Kumawat, Vikram Gayri, Kumawat Gopal Jagdish, Deepak Vyas
Abstract
India supplies a large share of the world’s generic medicines, yet its finished-dosage industry rests on imported active pharmaceutical ingredients (APIs), key starting materials (KSMs) and drug intermediates, most of them sourced from a single country. This review examines three linked themes: the extent and structure of India’s API import dependence, the regulatory framework that governs domestic manufacturing and quality, and the policy and industrial strategies intended to build self-reliance. Government, parliamentary, trade and industry sources were analysed narratively. Recent data show that API imports reached roughly US$7.4 billion in 2025, that five product categories account for about 84% of that value, and that China supplies more than 65% of every leading category and over 90% of several antibiotics and intermediates. Production Linked Incentive (PLI) and Bulk Drug Park schemes have created new capacity, but imports have not fallen in aggregate. Regulatory tightening, especially the revised Schedule M for Good Manufacturing Practice (GMP), raises quality but also imposes compliance costs on micro, small and medium enterprises (MSMEs). We argue that self-reliance is best framed as supply-chain resilience, not autarky, and we outline a prioritised strategy: targeting the most concentrated molecules, reviving fermentation-based antibiotic capacity, adopting green and continuous manufacturing, fixing cost and infrastructure disadvantages, streamlining API regulation, and building strategic stockpiles and diversified sourcing.
3. Metal–Organic Frameworks in Advanced Drug Delivery: Design Principles, Stimuli-Responsive Release and Translational Barriers
Surendra, Dilip Kumar, Jitendra Kumar, Deepak Vyas, Kumawat Gopal Jagdish
Abstract
Metal–organic frameworks (MOFs) are crystalline porous hybrids of metal nodes and organic linkers whose tunable porosity, chemistry and surface functionality make them attractive drug carriers. This review summarises the design principles that govern MOF drug carriers, the mechanisms of stimuli-responsive release, the evidence for therapeutic applications, and the barriers that separate laboratory success from clinical use. A narrative synthesis of peer-reviewed reviews and key primary studies retrieved from PubMed was complemented by a bibliometric count of PubMed records. The literature is growing fast: 2,368 PubMed records matched “metal-organic frameworks drug delivery” as of 6 October 2026, rising from 44 in 2016 to 507 in 2025. Design choices of metal, linker, size, loading method and surface coating determine capacity, stability and biocompatibility. Endogenous triggers (pH, glutathione, ATP, ions, enzymes) and exogenous triggers (light, temperature, ultrasound, magnetic field) can control release, and applications span cancer therapy, immunotherapy, oral and pulmonary delivery, antiparasitic and antibacterial treatment, and macromolecule delivery. Yet the same PubMed search returned no records indexed as clinical trials. The main barriers are incomplete toxicity and biodegradation data, scale-up and batch reproducibility, weak quality-control standards and an unsettled regulatory pathway. We propose a translation-oriented design framework that favours biocompatible metals and linkers, simple stimulus-responsive chemistries, scalable synthesis and early pharmacokinetic and safety studies.